LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China
CINCINNATI & SHANGHAI--(BUSINESS WIRE)--Sep 12, 2023--
Source: joplinglobe.com
Liberate Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Liberate Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Liberate Program Today - Breaking & Trending Today
LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Ph
-- Industry veteran brings more than 30 years of operational experience, in large pharma and emerging stage biotech, private and public companies, with extensive commercial experience and an established track record of financing in the capital markets-- Lerodalcibep, a novel, next generation PCSK9 inhibitor and the...
Source: pharmiweb.com